Enfortumab vedotin clinical trials
Also written Padcev, ASG-22CE and AGS-22M6E.
ClinicalTrials.gov finds 110 studies for enfortumab vedotin. How that becomes 57 here
Every study that search finds has been read, to see whether and how it gives enfortumab vedotin. ClinicalTrials.gov counts as of Nov 16, 2026. How drug pages count
- 110Found by its intervention search · See all 110 hereIt also reads titles, arm labels, keywords and descriptions, and counts the drug’s other names. Of these, 82 name it in an intervention entry. The counts it shows beside each synonym overlap: a study writing two names counts under both.
- −5
Mention it without giving it — earlier treatment, a protocol code, a title naming another drug
- Study of 2141-V11 in People With Non-muscle Invasive Bladder Cancer That Did Not Respond to Standard TreatmentNCT05126472 · Received before entry, as earlier neoadjuvant treatmentReport a problem
- Gemcitabine and Carboplatin After Progression on Enfortumab Vedotin and Pembrolizumab in Advanced/Metastatic Urothelial CarcinomaNCT07043972 · Received before entry; gemcitabine and carboplatin follow itReport a problem
- Study of Datopotamab Deruxtecan Plus Carboplatin or Cisplatin Versus Gemcitabine Plus Carboplatin or Cisplatin in Participants With Locally Advanced or Metastatic Urothelial CarcinomaNCT07129993 · Received before entry; the study treats progression after itReport a problem
- Trastuzumab Rezetecan in Advanced Solid Tumors Refractory to Standard TherapiesNCT07309770 · Earlier treatment named in eligibility, not givenReport a problem
- Consolidative Therapy After EV + Pembrolizumab in Muscle Invasive Bladder Cancer, REINFORCE TrialNCT07579195 · Received before entry; consolidative surgery or radiation followsReport a problem
- 105Give enfortumab vedotin to participants
- −17Observe patients on it, or give it outside a trial
- −1Use it as a tool: an imaging tracer or a test of drug response
- −4Compare another treatment with it
- −26Give it beside what is tested
- 57Test it: the count on this site
Get an email when these change. Save the enfortumab vedotin studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your alerts, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your alerts. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- 18 Dec 2019 · PADCEV · BLA 761137 (FDA, Drugs@FDA)
- European Union
- 13 Apr 2022 · Padcev · EMEA/H/C/005392 (EMA)
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Studies by the year they started
56 studies that test it; most in 2026 (13); 1 more planned to start later
| Year | Studies |
|---|---|
| 2011 | 1 |
| 2014 | 1 |
| 2017 | 3 |
| 2018 | 1 |
| 2019 | 2 |
| 2020 | 2 |
| 2021 | 5 |
| 2022 | 4 |
| 2023 | 7 |
| 2024 | 5 |
| 2025 | 12 |
| 2026 | 13 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 20 · Other 37
Astellas Pharma Global Development, Inc. (9) · National Cancer Institute (NCI) (3) · Memorial Sloan Kettering Cancer Center (3) · Merck Sharp & Dohme LLC (3) · Fox Chase Cancer Center (3) · Astellas Pharma Inc (3) · University of Utah (2) · Grupo Español Multidisciplinar de Melanoma (1)
Often tested with
Tested in the same studies.
Pembrolizumab (23) · Sacituzumab govitecan (5) · Trastuzumab deruxtecan (4) · Enfortumab Vedotin/Pembrolizumab Regimen (2) · Cisplatin (2) · Gemcitabine (2) · Niraparib (2) · Erdafitinib (1)
Related medicines
As reviewed, each with the page that says it.
Coming up
From the study records. Dates are the sponsors’ own estimates and often move.
Tested against it · 2 phase 3 studies under way
Enfortumab vedotin is the comparator. A study of two new drugs counts under both.
- 1Datopotamab deruxtecan · AstraZeneca · next primary completion Sep 2030
- 1Rilvegostomig · AstraZeneca · next primary completion Sep 2030
- 1SEPHB4-HSA · Vasgene Therapeutics, Inc · next primary completion Sep 2029
New treatments tested with it · 8 most studied
New when their studies opened, with enfortumab vedotin beside them; studies of each.
Reaching primary completion within a year · 17
Studies that test enfortumab vedotin.
- Dec 2026Testing Combination Erdafitinib and Enfortumab Vedotin in Metastatic Bladder Cancer After Treatment With Chemotherapy and ImmunotherapyPhase 1 · National Cancer Institute (NCI)
- Dec 2026Enfortumab Vedotin Plus Pembrolizumab for the Treatment of Locally Advanced or Metastatic Bladder Cancer of Variant HistologyPhase 2 · Emory University
- Dec 2026A Safety Study of Enfortumab Vedotin in Indian Adults With Urothelial CancerPhase 4 · Astellas Pharma Global Development, Inc.
- Jan 2027Pembrolizumab and Enfortumab Vedotin With Pembrolizumab Prior to and After Radical Nephroureterectomy for High-Risk Upper Tract Urothelial CancerPhase 2 · Jonsson Comprehensive Cancer Center
- Feb 2027Sacituzumab Govitecan Plus EV in Metastatic UCPhase 1/2 · Dana-Farber Cancer Institute
- Mar 2027A Study of Enfortumab Vedotin in People With Adenoid Cystic CarcinomaPhase 2 · Memorial Sloan Kettering Cancer Center
- Apr 2027EV + Toripalimab vs GC as Neoadjuvant Therapy in Locally Advanced/High-Risk MIBCPhase 2 · Peking University Third Hospital
- Jun 2027Enfortumab Vedotin and Pembrolizumab in People With Bladder CancerPhase 2 · Memorial Sloan Kettering Cancer Center
- Jun 2027PLUG-IN: Pembrolizumab Combined With Enfortumab Vedotin for Advanced Melanoma PatientsPhase 2 · Grupo Español Multidisciplinar de Melanoma
- Jun 2027A Study of Enfortumab Vedotin in People With Urothelial Carcinoma of the Upper Urinary TractPhase 2 · Memorial Sloan Kettering Cancer Center
Studies
Open first, then newest update. How each study uses enfortumab vedotin has had a first review, but it may not be perfect: check the study record before relying on it for anything important, and report a problem from its row. Some give it without naming it in an intervention entry: those were found by reading the record.
Testing it · 57
- A Study to Find Out if Enfortumab Vedotin Given With Pembrolizumab Helps People With Muscle-invasive Bladder Cancer Keep Their BladderRecruitingPhase 2Astellas Pharma Global Development, Inc.NCT07475806With pembrolizumab to keep the bladder in muscle-invasive cancerWritten as Enfortumab VedotinReport a problem
- Risk-Enabled Therapy After Initiating EV/Pembro for Bladder CancerRecruitingPhase 2Fox Chase Cancer CenterNCT07908979Neoadjuvant with pembrolizumab, then risk-adapted managementWritten as Enfortumab vedotinReport a problem
- Enfortumab Vedotin in Combination With Pembrolizumab vs. Concurrent Chemoradiotherapy (cCRT) in People With Muscle Invasive Bladder Cancer (EV-309)RecruitingPhase 3Astellas Pharma Global Development, Inc.NCT07566156With pembrolizumab against chemoradiotherapy to keep the bladderWritten as Enfortumab vedotinReport a problem
- Personalized Antibody-Drug Conjugate Therapy Based on RNA and Protein Testing for the Treatment of Advanced or Metastatic Solid Tumors (The ADC MATCH Screening and Treatment Trial)RecruitingPhase 2National Cancer Institute (NCI)NCT06311214In Nectin-4-high tumours, one biomarker cohortWritten as Enfortumab VedotinReport a problem
- Study of EV for Recurrent Endometrial CarcinomaRecruitingPhase 2William BradleyNCT07139977Alone in recurrent endometrial carcinomaWritten as Enfortumab VedotinReport a problem
- DEPECA-1 - A Phase II Study to Evaluate a First-line Systemic Therapy With Enfortumab Vedotin Plus Avelumab for Advanced and Metastatic Penile CarcinomaRecruitingPhase 2Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus NordwestNCT07110038With avelumab, first line in penile cancerWritten as enfortumab vedotinReport a problem
- Enfortumab Vedotin for the Treatment of Unresectable or Metastatic Radioiodine Refractory Differentiated Thyroid Cancer, Anaplastic Thyroid Cancer, Medullary Thyroid Cancer, or NUT CarcinomaNot yet recruitingPhase 2Northwestern UniversityNCT07863765Alone in aggressive thyroid cancers and NUT carcinomaWritten as Enfortumab VedotinReport a problem
- The Impact of Time-of-day Administration of EV/P on Objective Response Rate in Adults With Advanced Bladder CancerNot yet recruitingPhase 3Guliz OzgunNCT07346053Morning against afternoon dosing with pembrolizumabReport a problem
- Enfortumab Vedotin and Pembrolizumab Combined With Radiotherapy in Muscle Invasive Bladder CancerRecruitingPhase 1/2University of California, San FranciscoNCT06470282Dose found with pembrolizumab and radiotherapy, keeping the bladderWritten as Enfortumab VedotinReport a problem
- A Study of Enfortumab Vedotin in People With Adenoid Cystic CarcinomaRecruitingPhase 2Memorial Sloan Kettering Cancer CenterNCT06891560Alone in adenoid cystic carcinomaWritten as Enfortumab VedotinReport a problem
- Enfortumab Vedotin and Stereotactic Radiation for Localized Bladder CancerRecruitingPhase 1/2University of Texas Southwestern Medical CenterNCT06394570With stereotactic radiotherapy before cystectomyWritten as Enfortumab vedotinReport a problem
- N-803 in Combination With Pembrolizumab and Enfortumab Vedotin for Treatment of Urothelial CancerNot yet recruitingPhase 1ImmunityBio, Inc.NCT07217496A short course with pembrolizumab and N-803, first lineWritten as enfortumab vedotin (EV)Report a problem
- Protein-Matched ADC or PDC Umbrella Trial in Advanced Pancreatic and Breast CancerNot yet recruitingPhase 2Fudan UniversityNCT07825753In a Nectin-4 cohort for pancreatic and breast cancerWritten as Enfortumab vedotin (EV)Report a problem
- A Phase 2 Study Evaluating Bladder Preservation With Enfortumab Vedotin Plus Pembrolizumab in Patients With Muscle-Invasive Urothelial CancerNot yet recruitingPhase 2University of UtahNCT07822373With pembrolizumab to preserve the bladderWritten as Enfortumab vedotinReport a problem
- Neoadjuvant Enfortumab Vedotin Plus Pembrolizumab in Muscle-Invasive Bladder Cancer and Upper Tract Urothelial CarcinomaNot yet recruitingPhase 2University of FloridaNCT07643519With pembrolizumab before surgery or response-adapted bladder sparingReport a problem
- A Safety Study of Enfortumab Vedotin in Indian Adults With Urothelial CancerRecruitingPhase 4Astellas Pharma Global Development, Inc.NCT06862219Safety in Indian adults with urothelial cancerWritten as Enfortumab VedotinReport a problem
- Enfortumab Vedotin With or Without Pembrolizumab in Rare Genitourinary Tumors (E-VIRTUE)RecruitingPhase 2National Cancer Institute (NCI)NCT06041503Alone or with pembrolizumab in rare genitourinary tumoursWritten as Enfortumab vedotinReport a problem
- Enfortumab Vedotin Plus Pembrolizumab With Selective Bladder Sparing for Treatment of Muscle-invasive Bladder CancerRecruitingPhase 2Matthew GalskyNCT06809140With pembrolizumab for selective bladder sparingWritten as Enfortumab vedotinReport a problem
- Enfortumab Vedotin Plus Pembrolizumab for the Treatment of Locally Advanced or Metastatic Bladder Cancer of Variant HistologyRecruitingPhase 2Emory UniversityNCT05756569With pembrolizumab in bladder cancer of variant histologyWritten as Enfortumab VedotinReport a problem
- Study of Neoadjuvant Enfortumab Vedotin and Pembrolizumab in Upper Tract Urothelial CancerRecruitingPhase 2University of Michigan Rogel Cancer CenterNCT06356155With pembrolizumab before surgery for upper tract urothelial cancerWritten as Enfortumab vedotinReport a problem
See all 57 studies that test enfortumab vedotin →
Tested on its own · 19 — no other medicine in its arm
- Study of EV for Recurrent Endometrial CarcinomaRecruitingPhase 2William BradleyNCT07139977Alone in recurrent endometrial carcinomaWritten as Enfortumab VedotinReport a problem
- Enfortumab Vedotin for the Treatment of Unresectable or Metastatic Radioiodine Refractory Differentiated Thyroid Cancer, Anaplastic Thyroid Cancer, Medullary Thyroid Cancer, or NUT CarcinomaNot yet recruitingPhase 2Northwestern UniversityNCT07863765Alone in aggressive thyroid cancers and NUT carcinomaWritten as Enfortumab VedotinReport a problem
- A Study of Enfortumab Vedotin in People With Adenoid Cystic CarcinomaRecruitingPhase 2Memorial Sloan Kettering Cancer CenterNCT06891560Alone in adenoid cystic carcinomaWritten as Enfortumab VedotinReport a problem
- Enfortumab Vedotin and Stereotactic Radiation for Localized Bladder CancerRecruitingPhase 1/2University of Texas Southwestern Medical CenterNCT06394570With stereotactic radiotherapy before cystectomyWritten as Enfortumab vedotinReport a problem
- A Safety Study of Enfortumab Vedotin in Indian Adults With Urothelial CancerRecruitingPhase 4Astellas Pharma Global Development, Inc.NCT06862219Safety in Indian adults with urothelial cancerWritten as Enfortumab VedotinReport a problem
- Enfortumab Vedotin With Radiation for Locally Advanced Bladder Cancer (CONSOLIDATE)RecruitingPhase 1/2M.D. Anderson Cancer CenterNCT06434350With radiotherapy for locally advanced bladder cancerWritten as Enfortumab VedotinReport a problem
- Enfortumab Vedotin for the Treatment of Patients With Metastatic or Unresectable Squamous Cell Carcinoma of the PenisRecruitingPhase 2Mayo ClinicNCT06104618Alone in penile squamous cell carcinomaWritten as Enfortumab VedotinReport a problem
- Ph II Study of Enfortumab Vedotin in Patients With Advanced or Metastatic CRC or HCCRecruitingPhase 2H. Lee Moffitt Cancer Center and Research InstituteNCT06553885Alone in colorectal cancer and hepatocellular carcinomaWritten as Enfortumab VedotinReport a problem
- Enfortumab Vedotin in Patients With Advanced Small Bowel Adenocarcinoma Refractory or Intolerant to Platinum-based Combination TherapyRecruitingPhase 2National Cancer Center, JapanNCT07347314Alone in small bowel adenocarcinoma after platinumWritten as Enfortumab vedotinReport a problem
- A Study to Evaluate Enfortumab Vedotin (ASG-22CE) in Chinese Participants With Locally Advanced or Metastatic Urothelial Cancer Who Previously Received Platinum-containing Chemotherapy and Programmed Cell Death Protein-1 ( PD 1) / (Programmed Death Ligand-1 (PD-L1) Inhibitor TherapyCompletedPhase 2Astellas Pharma China, Inc.NCT04995419Alone in Chinese patients after platinum and PD-1 therapyWritten as Enfortumab vedotinReport a problem
- A Study of Intravesical Enfortumab Vedotin For Treatment of Patients With Non-muscle Invasive Bladder Cancer (NMIBC)TerminatedPhase 1Astellas Pharma Global Development, Inc.NCT05014139Given into the bladder for non-muscle-invasive bladder cancerWritten as Enfortumab vedotinReport a problem
- A Study of Enfortumab Vedotin in People With Urothelial Carcinoma of the Upper Urinary TractActive, not recruitingPhase 2Memorial Sloan Kettering Cancer CenterNCT05868265Alone before surgery for upper tract urothelial cancerWritten as Enfortumab VedotinReport a problem
- A Study of Escalating Doses of ASG-22CE Given as Monotherapy in Subjects With Metastatic Urothelial Cancer and Other Malignant Solid Tumors That Express Nectin-4CompletedPhase 1Astellas Pharma Global Development, Inc.NCT02091999Dose escalation in urothelial and other Nectin-4 tumoursWritten as enfortumab vedotinReport a problem
- Enfortumab Vedotin as Monotherapy in Patients With Metastatic Castration-Resistant Prostate CancerActive, not recruitingPhase 2University of UtahNCT04754191Alone in metastatic castration-resistant prostate cancerWritten as Enfortumab vedotinReport a problem
- A Study to Evaluate Enfortumab Vedotin Versus (vs) Chemotherapy in Subjects With Previously Treated Locally Advanced or Metastatic Urothelial Cancer (EV-301)CompletedPhase 3Astellas Pharma Global Development, Inc.NCT03474107Against chemotherapy in previously treated urothelial cancerWritten as Enfortumab VedotinReport a problem
- Enfortumab Vedotin in Previously Treated Locally Advanced or Metastatic Pancreatic Cancer (EPIC)Active, not recruitingPhase 2University of Kansas Medical CenterNCT05915351Alone in previously treated pancreatic cancerWritten as Enfortumab vedotinReport a problem
- A Study of Enfortumab Vedotin in Japanese Subjects With Locally Advanced or Metastatic Urothelial CarcinomaCompletedPhase 1Astellas Pharma IncNCT03070990Safety and blood levels in Japanese patients with urothelial cancerWritten as Enfortumab vedotinReport a problem
- A Study of Enfortumab Vedotin for Patients With Locally Advanced or Metastatic Urothelial Bladder CancerCompletedPhase 2Astellas Pharma IncNCT03219333Alone after checkpoint inhibitors in urothelial cancerWritten as Enfortumab vedotinReport a problem
- A Study of the Safety and Pharmacokinetics of AGS-22M6E in Subjects With Malignant Solid Tumors That Express Nectin-4CompletedPhase 1Astellas Pharma IncNCT01409135First-in-human doses in Nectin-4-expressing tumoursWritten as AGS-22M6EReport a problem
Tested with established drugs · 4 — they are given beside it
- Enfortumab Vedotin and Pembrolizumab Combined With Radiotherapy in Muscle Invasive Bladder CancerRecruitingPhase 1/2University of California, San FranciscoNCT06470282Dose found with pembrolizumab and radiotherapy, keeping the bladderWritten as Enfortumab VedotinReport a problem
- A Study to Evaluate Enfortumab Vedotin in Subjects With Locally Advanced or Metastatic Malignant Solid Tumors (EV-202)Active, not recruitingPhase 2Astellas Pharma Global Development, Inc.NCT04225117Alone across solid tumours; with pembrolizumab in head and neckWritten as enfortumab vedotinReport a problem
- A Study of Enfortumab Vedotin Alone or With Other Therapies for Treatment of Urothelial CancerTerminatedPhase 1/2Astellas Pharma Global Development, Inc.NCT03288545Alone or with pembrolizumab or chemotherapy in urothelial cancerWritten as enfortumab vedotin (EV)Report a problem
- Enfortumab Vedotin Schedule De-escalation in Metastatic Urothelial CarcinomaActive, not recruitingPhase 2Fox Chase Cancer CenterNCT05923190Schedule de-escalation, alone and with pembrolizumabWritten as Enfortumab vedotinReport a problem
Tested in a combination · 34 — another drug in the study is under test too
- A Study to Find Out if Enfortumab Vedotin Given With Pembrolizumab Helps People With Muscle-invasive Bladder Cancer Keep Their BladderRecruitingPhase 2Astellas Pharma Global Development, Inc.NCT07475806With pembrolizumab to keep the bladder in muscle-invasive cancerWritten as Enfortumab VedotinReport a problem
- Risk-Enabled Therapy After Initiating EV/Pembro for Bladder CancerRecruitingPhase 2Fox Chase Cancer CenterNCT07908979Neoadjuvant with pembrolizumab, then risk-adapted managementWritten as Enfortumab vedotinReport a problem
- Enfortumab Vedotin in Combination With Pembrolizumab vs. Concurrent Chemoradiotherapy (cCRT) in People With Muscle Invasive Bladder Cancer (EV-309)RecruitingPhase 3Astellas Pharma Global Development, Inc.NCT07566156With pembrolizumab against chemoradiotherapy to keep the bladderWritten as Enfortumab vedotinReport a problem
- Personalized Antibody-Drug Conjugate Therapy Based on RNA and Protein Testing for the Treatment of Advanced or Metastatic Solid Tumors (The ADC MATCH Screening and Treatment Trial)RecruitingPhase 2National Cancer Institute (NCI)NCT06311214In Nectin-4-high tumours, one biomarker cohortWritten as Enfortumab VedotinReport a problem
- DEPECA-1 - A Phase II Study to Evaluate a First-line Systemic Therapy With Enfortumab Vedotin Plus Avelumab for Advanced and Metastatic Penile CarcinomaRecruitingPhase 2Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus NordwestNCT07110038With avelumab, first line in penile cancerWritten as enfortumab vedotinReport a problem
- The Impact of Time-of-day Administration of EV/P on Objective Response Rate in Adults With Advanced Bladder CancerNot yet recruitingPhase 3Guliz OzgunNCT07346053Morning against afternoon dosing with pembrolizumabReport a problem
- N-803 in Combination With Pembrolizumab and Enfortumab Vedotin for Treatment of Urothelial CancerNot yet recruitingPhase 1ImmunityBio, Inc.NCT07217496A short course with pembrolizumab and N-803, first lineWritten as enfortumab vedotin (EV)Report a problem
- Protein-Matched ADC or PDC Umbrella Trial in Advanced Pancreatic and Breast CancerNot yet recruitingPhase 2Fudan UniversityNCT07825753In a Nectin-4 cohort for pancreatic and breast cancerWritten as Enfortumab vedotin (EV)Report a problem
- A Phase 2 Study Evaluating Bladder Preservation With Enfortumab Vedotin Plus Pembrolizumab in Patients With Muscle-Invasive Urothelial CancerNot yet recruitingPhase 2University of UtahNCT07822373With pembrolizumab to preserve the bladderWritten as Enfortumab vedotinReport a problem
- Neoadjuvant Enfortumab Vedotin Plus Pembrolizumab in Muscle-Invasive Bladder Cancer and Upper Tract Urothelial CarcinomaNot yet recruitingPhase 2University of FloridaNCT07643519With pembrolizumab before surgery or response-adapted bladder sparingReport a problem
- Enfortumab Vedotin With or Without Pembrolizumab in Rare Genitourinary Tumors (E-VIRTUE)RecruitingPhase 2National Cancer Institute (NCI)NCT06041503Alone or with pembrolizumab in rare genitourinary tumoursWritten as Enfortumab vedotinReport a problem
- Enfortumab Vedotin Plus Pembrolizumab With Selective Bladder Sparing for Treatment of Muscle-invasive Bladder CancerRecruitingPhase 2Matthew GalskyNCT06809140With pembrolizumab for selective bladder sparingWritten as Enfortumab vedotinReport a problem
- Enfortumab Vedotin Plus Pembrolizumab for the Treatment of Locally Advanced or Metastatic Bladder Cancer of Variant HistologyRecruitingPhase 2Emory UniversityNCT05756569With pembrolizumab in bladder cancer of variant histologyWritten as Enfortumab VedotinReport a problem
- Study of Neoadjuvant Enfortumab Vedotin and Pembrolizumab in Upper Tract Urothelial CancerRecruitingPhase 2University of Michigan Rogel Cancer CenterNCT06356155With pembrolizumab before surgery for upper tract urothelial cancerWritten as Enfortumab vedotinReport a problem
- Pembrolizumab and Enfortumab Vedotin With Pembrolizumab Prior to and After Radical Nephroureterectomy for High-Risk Upper Tract Urothelial CancerRecruitingPhase 2Jonsson Comprehensive Cancer CenterNCT05775471With pembrolizumab before nephroureterectomy for upper tract cancerWritten as Enfortumab VedotinReport a problem
- Enfortumab Vedotin + Pembrolizumab Induction to Spare the Bladder in MIBCNot yet recruitingPhase 2The Netherlands Cancer InstituteNCT07663747Induction with pembrolizumab, then response-adapted bladder sparingWritten as Enfortumab VedotinReport a problem
- EV + Toripalimab vs GC as Neoadjuvant Therapy in Locally Advanced/High-Risk MIBCRecruitingPhase 2Peking University Third HospitalNCT07647289With toripalimab against chemotherapy before cystectomyWritten as enfortumab vedotin (EV)Report a problem
- Precision Treatment of Recurrent/Metastatic Salivary Gland Carcinoma Guided by Molecular TypingRecruitingPhase 2Peking Union Medical CollegeNCT06145308In one Nectin-4 cohort for salivary gland carcinomaWritten as enfortumab vedotinReport a problem
- Pembrolizumab Maintenance After Enfortumab Vedotin (EV)/Pembro Induction in Front-Line Metastatic Urothelial CarcinomaRecruitingPhase 2Fox Chase Cancer CenterNCT07221942Limited to 18 weeks of induction before pembrolizumab maintenanceWritten as Enfortumab vedotinReport a problem
- Circulating Tumor DNA Response In Urothelial CancerRecruitingPhase 2University of OklahomaNCT07183319Stopped after 24 weeks, guided by ctDNA, pembrolizumab continuedWritten as Pembrolizumab & Enfortumab Vedotin (PEV)Report a problem
Showing 20 of 34. See all 34 →
Beside an established treatment under test · 5 — an approved drug, surgery or radiation is what the study tests
Tested with enfortumab vedotin: Surgery or a procedure 3 · nadofaragene firadenovec 1 · datopotamab deruxtecan 1 · olomorasib 1 · cabozantinib 1
- Neoadjuvant Intravesical Nadofaragene Firadenovec With Enfortumab Vedotin and Pembrolizumab for the Treatment of Muscle Invasive Bladder Cancer, TRIFECTA TrialNot yet recruitingPhase 2University of WashingtonNCT07332351In every armStandard partner of pembrolizumab; nadofaragene firadenovec is addedWritten as Enfortumab VedotinReport a problem
- A Study of Dato-DXd in Participants With Solid Tumors [TROPION-PanTumor04 (TP04)]RecruitingPhase 1/2Daiichi SankyoNCT07890714With pembrolizumab in every arm; Dato-DXd is addedWritten as Enfortumab Vedotin (EV)Report a problem
- Enfortumab Vedotin and Pembrolizumab With Cystectomy and/or Ureterectomy for Locally Advanced or Metastatic Bladder and Upper Urothelial Tract Cancer, CAST-AI TrialRecruitingPhase 4Mayo ClinicNCT06764095In every armStandard treatment before cytoreductive surgery, which is testedWritten as Enfortumab VedotinReport a problem
- Therapeutic Plasma Exchange With Enfortumab Vedotin and Pembrolizumab for Treatment of Bladder CancersRecruitingPhase 2Mayo ClinicNCT07087860Given after plasma exchange, which is what is testedWritten as Enfortumab VedotinReport a problem
- Cabozantinib in Combination With Enfortumab Vedotin for Locally Advanced or Metastatic Urothelial CancerRecruitingPhase 1Emory UniversityNCT04878029In every armBase treatment; cabozantinib is added and dosedWritten as Enfortumab VedotinReport a problem
Beside a new treatment under test · 14 — a new drug, cell therapy or vaccine is what the study tests
New treatments tested with enfortumab vedotin: sitravatinib 2 · vepugratinib 2 · sacituzumab govitecan 1 · zimberelimab 1 · domvanalimab 1 · intismeran autogene 1 · Favezelimab/Pembrolizumab Formulation 1 · Vibostolimab/Pembrolizumab MK-7684A 1
- FORAGER-1: A Study of Vepugratinib (LY3866288; LOXO-435) in Participants With Cancer With a Change in a Gene Called FGFR3RecruitingPhase 1Eli Lilly and CompanyNCT05614739Partner of new vepugratinib with pembrolizumab in one cohortWritten as enfortumab vedotinReport a problem
- A Study of ASP2998 Given by Itself and Given With Standard Therapies in People With Solid TumorsRecruitingPhase 1/2Astellas Pharma Global Development, Inc.NCT07287995Partner of new ASP2998 in a combination cohortWritten as Enfortumab VedotinReport a problem
- Enfortumab Vedotin, Pembrolizumab and Quemliclustat for the Treatment of Unresectable Locally Advanced and Metastatic Urothelial CancerRecruitingPhase 1/2Fred Hutchinson Cancer CenterNCT07667335In every armWith pembrolizumab, partner of new quemliclustatWritten as Enfortumab VedotinReport a problem
- Symbiotic-GU-06: A Study to Learn About PF-08634404 Alone or In Combination With Enfortumab Vedotin in Urothelial CancerRecruitingPhase 1/2PfizerNCT07421700Partner of new PF-08634404 in untreated urothelial cancerWritten as Enfortumab VedotinReport a problem
- A Study of Vepugratinib (LY3866288) in Participants With Cancer in the Urinary TractRecruitingPhase 3Eli Lilly and CompanyNCT07218380In every armGiven in every arm with pembrolizumab; new vepugratinib is addedReport a problem
- KEYMAKER-U04 Substudy 04D: A Clinical Study of New Treatments Given With Enfortumab Vedotin and Pembrolizumab in People With Urothelial Cancer (MK-3475-04D/KEYMAKER-U04)RecruitingPhase 1/2Merck Sharp & Dohme LLCNCT07232602In every armGiven with pembrolizumab beside new MK-3120Report a problem
- A Study of Ivonescimab in Combination With Enfortumab Vedotin vs Pembrolizumab in Combination With Enfortumab Vedotin in Metastatic Urothelial CarcinomaRecruitingPhase 2/3Summit TherapeuticsNCT07815665In every armGiven in every arm; ivonescimab is compared with pembrolizumabWritten as enfortumab vedotin (EV)Report a problem
- CVL006 Combination Therapy in Advanced Solid TumorsNot yet recruitingPhase 1/2Convalife (Shanghai) Co., Ltd.NCT07157956Partner of new CVL006 in one urothelial cohortWritten as CVL006 in combination with Enfortumab VedotinReport a problem
- Study of Sacituzumab Govitecan in Participants With Urothelial Cancer That Cannot Be Removed or Has SpreadActive, not recruitingPhase 2Gilead SciencesNCT03547973Partner of sacituzumab govitecan and zimberelimab in one cohortWritten as Enfortumab VedotinReport a problem
- Study of Sitravatinib With or Without Other Anticancer Therapies Receiving Clinical Benefit From Parent StudyCompletedPhase 2/3Mirati Therapeutics Inc.NCT04887870In every armPartner of new sitravatinib for people from earlier studiesWritten as Enfortumab Vedotin-EjfvReport a problem
- A Clinical Study of Intismeran Autogene (V940) Treatment and Pembrolizumab in People With Bladder Cancer (V940-005/INTerpath-005)Active, not recruitingPhase 1/2Merck Sharp & Dohme LLCNCT06305767Partner of new intismeran autogene in one cohortWritten as Enfortumab VedotinReport a problem
- A Study of Efficacy and Safety of Pembrolizumab Plus Enfortumab Vedotin (EV) +/- Investigational Agents in First-Line Metastatic Urothelial Carcinoma (mUC) (MK-3475-04B/KEYMAKER-U04)Active, not recruitingPhase 1/2Merck Sharp & Dohme LLCNCT05845814In every armGiven in every arm; new favezelimab or vibostolimab coformulations are addedWritten as EVReport a problem
- A Study of Evorpacept (ALX148) With Enfortumab Vedotin for Subjects With Urothelial Carcinoma (ASPEN-07)CompletedPhase 1ALX Oncology Inc.NCT05524545In every armPartner of new evorpacept in urothelial cancerWritten as Enfortumab VedotinReport a problem
- A Phase 2 Study of Sitravatinib in Combination With PD-(L)1 Checkpoint Inhibitor Regimens in Patients With Advanced or Metastatic Urothelial CarcinomaTerminatedPhase 2Mirati Therapeutics Inc.NCT03606174Partner of new sitravatinib in one cohortWritten as Enfortumab vedotinReport a problem
Beside supportive care · 5 — a supportive treatment or test is studied
- Acupuncture and Exercise for EV-Pembro-Induced Peripheral NeuropathyRecruitingNot applicableDana-Farber Cancer InstituteNCT07548476People on it try acupuncture and exercise for neuropathyReport a problem
- Study of GB-4362 With Enfortumab Vedotin and Pembrolizumab for Advanced Urothelial CancerRecruitingPhase 1Generate BiomedicinesNCT07484022In every armIts payload is what new GB-4362 is meant to neutraliseWritten as enfortumab vedotin (EV)Report a problem
- Study of Peripheral Neuropathy in Patients With Advanced Urothelial Cancer Treated With Enfortumab Vedotin and Pembrolizumab With Supportive Neuridase (ENDEAVOR)Not yet recruitingNot applicableUniversity of FlorenceNCT07629700In every armStandard treatment beside supportive Neuridase for neuropathyWritten as enfortumab vedotin (EV)Report a problem
- Extracellular Vesicles and Chemotherapy-Induced Peripheral NeuropathyRecruitingNot applicableFondazione IRCCS Ca' Granda, Ospedale Maggiore PoliclinicoNCT07558447Standard treatment while neuropathy biomarkers are measuredReport a problem
- Optimal Methods to Characterize ADC Resistance in Solid Tumors and Identify Clinically Useful BiomarkersRecruitingPhase 2UNICANCERNCT07259226Standard treatment in which resistance biomarkers are studiedReport a problem
One option of several · 2 — a test or a strategy chooses among drugs
- PTC-guided Neoadjuvant Therapy For Muscle-invasive Bladder CancerNot yet recruitingPhase 2The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical SchoolNCT07690878One option chosen by tumour-cell testing before cystectomyReport a problem
- Probiotics in Advanced Urothelial CarcinomaRecruitingPhase 2Sun Yat-sen UniversityNCT06904573In every armOne immunotherapy-based option beside a probiotic under testWritten as Enfortumab VedotinReport a problem
As the comparator · 4 — what is tested is compared with enfortumab vedotin
- An Open-label Study to Investigate the Efficacy and Safety of Dato-DXd + Rilvegostomig vs SoC in Adult Participants With High-risk MIUCRecruitingPhase 3AstraZenecaNCT07720284One standard-care option in the comparator armWritten as Enfortumab vedotinReport a problem
- Sacituzumab Tirumotecan vs MMAE-ADCs in Advanced Urothelial Carcinoma (FUSCC-SPARE-UC-01)Not yet recruitingPhase 2Fudan UniversityNCT07662863One MMAE-based option in the comparator arm, against new sac-TMTReport a problem
- SYS6002 vs PADCEV in Patients With Advanced Urothelial CarcinomaNot yet recruitingPhase 2CSPC Megalith Biopharmaceutical Co.,Ltd.NCT07374549Comparator for new Nectin-4 conjugate SYS6002Written as enfortumab vedotinReport a problem
- Modular Trial of sEphB4-HSA in EphrinB2-High Solid TumorsRecruitingPhase 2/3Vasgene Therapeutics, IncNCT06493552Comparator with pembrolizumab for new sEphB4-HSAWritten as Enfortumab vedotinReport a problem
Observed · 17 — patients on it are followed, or it is given outside a trial
- A Study to Survey Adults in South Korea With Cancer Who Receive PADCEV InjectionRecruitingAstellas Pharma Korea, Inc.NCT06011954Post-marketing surveillance in South KoreaWritten as Enfortumab VedotinReport a problem
- Peripheral Neuropathy in Patients Receiving Enfortumab Vedotin and Pembrolizumab as Perioperative Systemic Therapy for Urothelial CarcinomaRecruitingComprehensive Cancer Center Munich (CCCM)NCT07870577Neuropathy observed during perioperative use with pembrolizumabReport a problem
- Perioperative Systemic Therapies in Muscle-Invasive Bladder Cancer (GUARDIANS)RecruitingLMU KlinikumNCT07855926Perioperative use observed in a bladder cancer registryReport a problem
- Real-World Outcomes of First-Line Treatment of Metastatic or Locally Advanced Upper Tract Urothelial Carcinoma With Enfortumab Vedotin Plus Pembrolizumab : A French Multicenter Retrospective Observational StudyEnrolling by invitationCentre Hospitalier Universitaire de NīmesNCT07633353Real-world first-line use in upper tract urothelial cancerReport a problem
- A Study of Neuropathy Caused by Enfortumab Vedotin in People With Urothelial CarcinomaRecruitingMemorial Sloan Kettering Cancer CenterNCT07390617Nerve tests in patients receiving itReport a problem
- Ablative Therapy of Oligometastatic Tumor After Response to Conventional First Line TreatmentNot yet recruitingChirecNCT07545486One first-line treatment before local ablative therapy, observedReport a problem
- Feasibility Study of Urinary cfDNA Analysis as a Non-invasive Monitoring Tool in Patients With Prostate or Bladder CancerNot yet recruitingInstitut Cancerologie de l'OuestNCT07468838One treatment cohort in a urine ctDNA monitoring studyReport a problem
- Peripheral Neuropathy in Patients Receiving Enfortumab Vedotin and Pembrolizumab as First Line Treatment for Metastatic or Locally Advanced Urothelial CarcinomaRecruitingComprehensive Cancer Center Munich (CCCM)NCT06657157Neuropathy observed during first-line use with pembrolizumabReport a problem
- International Multicentric Retrospective Study on the Use of EV+P as First-line Therapy in Patients With la/mUCNot yet recruitingAron Research Foundation EtsNCT07420855Real-world first-line use with pembrolizumabReport a problem
- Observational Study of the Effectiveness of Funded Drugs for Genitourinary Tumors.RecruitingSpanish Oncology Genito-Urinary GroupNCT06724159Real-world effectiveness after Spanish public fundingWritten as enfortumab vedotinReport a problem
- Management of Cisplatin-Ineligible Patients With Metastatic Bladder Cancer and The Role of Geriatric AssessmentsRecruitingDana-Farber Cancer InstituteNCT06138561Among standard treatments observed in older cisplatin-ineligible patientsReport a problem
- Criteria for Selecting First-line Metastatic Treatment for Patients With Urothelial CarcinomaRecruitingUniversity Hospital, Strasbourg, FranceNCT07339878First-line treatment choice observed in urothelial cancerReport a problem
- Neurological Function in Patients With Locally Advanced or Metastatic Urothelial Carcinoma Treated With Enfortumab Vedotin-Based TherapyNot yet recruitingNational Taiwan University HospitalNCT07072637Neuropathy assessed in patients on itReport a problem
- A Biomarker Study to Predict Treatment Outcomes of Enfortumab Vedotin in Advanced Urothelial CarcinomaActive, not recruitingNational Taiwan University Clinical Trial CenterNCT07063758Biomarkers of response in patients treated with itReport a problem
- Association Between Drug-related Cutaneous Adverse Events and Progression Free Survival in Patients Treated with Enfortumab VedotinCompletedHospices Civils de LyonNCT06682845Skin side effects and survival in patients treated with itReport a problem
- Evaluation of Reporting of Antibody-Drug Conjugate Associated Sepsis-related ToxicitiesCompletedCentral South UniversityNCT05349383Sepsis reports with antibody-drug conjugates, from FAERSReport a problem
- An Expanded Access Treatment Protocol of Enfortumab Vedotin in Subjects With Locally Advanced or Metastatic Urothelial CarcinomaApproved for marketingAstellas Pharma Global Development, Inc.NCT04136808Expanded access before approval in urothelial cancerWritten as enfortumab vedotin (EV)Report a problem
As a tool · 1 — an imaging tracer or a test of drug response
What changed recently
From the registry's own updates since Oct 18, 2026.
Newly registered1
- Risk-Enabled Therapy After Initiating EV/Pembro for Bladder CancerNov 2, 2026NCT07908979
Codes
What other systems call enfortumab vedotin · ClinicalTrials.gg INT001132
- MeSH (NLM) C000632577enfortumab vedotinConfirmed ClinicalTrials.gov, NLM
- UNII (FDA) DLE8519RWMENFORTUMAB VEDOTINConfirmed FDA, NLM, Wikidata
- RxNorm 2268306One source FDA
- Wikidata Q19904068enfortumab vedotinConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C114500Enfortumab VedotinOne source FDA
- DrugBank DB13007One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C000632577 | enfortumab vedotin | Confirmed ClinicalTrials.gov, NLM |
| UNII (FDA) | DLE8519RWM | ENFORTUMAB VEDOTIN | Confirmed FDA, NLM, Wikidata |
| RxNorm | 2268306 | — | One source FDA |
| Wikidata | Q19904068 | enfortumab vedotin | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C114500 | Enfortumab Vedotin | One source FDA |
| DrugBank | DB13007 | — | One source Wikidata |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.